Pharma Focus Asia
KP - Sustainable Packaging Solutions

SEKISUI Diagnostics Invests US$ 18.6 million in cGMP Microbial Capacity Expansion


Sekisui Diagnostics announced its plans to invest US$ 18.6 million (£14.4 million) in biopharma CDMO business to expand cGMP microbial capacity located at its existing site in Maidstone.


The new cGMP certified microbial fermentation and purification suites are expected to accommodate production scales up to 1,000L, complementing its existing capabilities that range from 20L to 5,000L fermentation scale.

The new facility and cGMP upgrades will help Sekisui take on drug substance contract manufacturing for its programs entering clinical trial phase.

The new investment made in cGMP capacity expansion will better serve the biopharma customers with much needed cGMP microbial CDMO production capacity.

The project is expected to be completed by the second half of 2022.


NameSEKISUI Diagnostics
BudgetUS$ 18.6 million (£14.4 million)
Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024Gibco Adherent Kidney Media PanelTFS - ODW - The Technology Debate: Single-Use vs. Stainless SteelAsia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 20244th Middle East Pharmacoeconomics and Drug Policy Summit 2024Digital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference
Searching for an end-to-end patient tech solution?